AUM Biosciences partners with National Cancer Centre Singapore (NCCS) to develop new cancer drugs
With an aim to develop new cancer drugs for Asian cancer patients, AUM Biosciences is proud to announce our collaboration with the National Cancer Centre Singapore (NCCS) on a joint research that will use precision and digital medicine techniques. Our combined efforts will shorten the time that it would normally take to test and develop new drugs.
The collaboration will combine NCCS’ highly-regarded Patient Derived Xenograft (PDX) laboratory model capabilities and knowledge on drug discovery, with AUM Biosciences’ expertise in clinical drug development. With NCCS’ niche in Asian-specific diseases and AUM’s focus on Asia-centric cancer treatments, this collaboration between our two Singapore parties will deliver huge benefits for patients here in Singapore and in the region.
About AUM Biosciences
AUM Biosciences (AUM) is an oncology-focused biotechnology company that aims to accelerate the development of innovative, affordable cancer medicines for patients in Asia and around the world. AUM Biosciences will harness the power of precision medicine and digital technologies to enhance the therapeutic and economic value for patients, physicians and our partners. AUM Biosciences partners with research institutions, pharmaceutical companies to acquire oncology drugs that address unmet medical needs. AUM Biosciences focuses on early-stage small molecule development of innovative medicines for the treatment of Asian-prevalent cancers prevalent, or has a growing trend in Asia, with an emphasis on small molecule based drug design. AUM Biosciences was founded by industry veterans with over 35 years of combined oncology drug development experiences.
For media enquiries, please contact:
Ms Rachel Tan
Manager, Corporate Communications
Office: 6236 9535
HP: 9754 0842
Ms Gillian Tan
Senior Executive, Corporate Communications
Office: 6236 9529
HP: 8157 3671
Manager, PR & Communications